PARP Inhibitor Biomarkers Market Size Share Trends Forecast 2027

1. PARP INHIBITOR BIOMARKERS MARKET ANALYSIS INDUSTRY INSIGHTS, TRENDS, OUTLOOK, AND OPPORTUNITY ANALYSIS, 2020–2027 © Coherent market Insights. All Rights Reserved © Coherent market Insights. All Rights Reserved

2. REPORT DESCRIPTION PARP Inhibitor Biomarkers Market - Overview Global PARP Inhibitor Biomarkers Market, by Product & Services (Product Type (Kits and Assays) and Services (BRCA 1 & 2 Testing, HRD Testing, HRR Testing and Others)), by Application (Breast Cancer, Ovarian Cancer, and Others (Prostate, Pancreatic, etc.) and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) was valued at US$ 374.9 million in 2019, and is projected to exhibit a CAGR of 24.5% over the forecast period (2019–2027), as highlighted in a new report published by Coherent Market Insights. An increasing number of research and development activities and government support to spread awareness about precision medicines such as DNA repair drugs is expected to drive the global PARP inhibitor biomarkers market growth during the forecast period For instance, in February 2019, on the occasion of World Cancer Day, the Union for International Cancer Control (UICC) launched a 3-year campaign ‘I Am and I Will’ to inspire and encourage individuals, the health community, and governments to improve public awareness and access to early detection, screening, and diagnosis of cancer. Moreover, in February 2019, the government of Australia announced an investment of US$ 1.6 Mn in an ovarian cancer project. Browse Research Reports: https://www.coherentmarketinsights.com/market-insight/parp- inhibitor-biomarkers-market-3762 © Coherent market Insights. All Rights Reserved

3. REPORT DESCRIPTION Furthermore, the government of Australia is also trying to reduce the cost of ovarian cancer treatment by listing ovarian cancer drugs such as Lynparza in the Pharmaceutical Benefits Scheme which is expected to help patients save around US$ 90,000 per year. Moreover, the increasing research and development of new products is expected to drive the market growth during the forecast period. For instance, in June 2018, researchers from Vall d'Hebron Institute of Oncology (VHIO) investigated in vivo mechanisms of PARPi resistance in patient-derived tumor xenografts (PDX) models generated by implanting tumor samples from patients with a germline BRCA1/2 mutation and breast or ovarian cancer to subsequently establish sensitivity or resistance to PARPi. Browse 27 Market Data Tables and 26 Figures spread through 154 Pages and in-depth TOC on PARP Inhibitor Biomarkers Market, Global Forecast to 2027, by Product & Services (Product Type (Kits and Assays) and Services (BRCA 1 & 2 Testing, HRD Testing, HRR Testing and Others), by Application (Breast Cancer, Ovarian Cancer, and Others (Prostate, Pancreatic, etc.), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa). The project Ovarian Cancer Australia is based on psychosocial support management providing care and support to ovarian cancer patients in Australia through tele-health services. Request a Sample copy of this reports: https://www.coherentmarketinsights.com/insight/request-sample/3762 © Coherent market Insights. All Rights Reserved

4. REPORT DESCRIPTION Key players operating in the market are focused on collaboration and acquisition strategies in order to expand their product portfolio and strengthen their presence in the global market. For instance, in December 2018, NeoGenomics Laboratories, Inc. acquired Genoptix, Inc., a leading clinical oncology laboratory specializing in hematology and solid tumor testing. The acquisition has helped NeoGenomics to extend its reach to oncology practices and accelerated the company’s progress towards achieving growth objectives. Key Takeaways of the Global PARP Inhibitor Biomarkers Market: The global PARP inhibitor biomarkers market is expected to exhibit a CAGR of 5% over the forecast period owing to an increasing incidence of breast cancer. According to GLOBOCAN statistics 2018, an estimated 43.6% new cases of breast cancer were registered in Asia Pacific in 2018 Among product & services, the product type segment is expected to dominate the global PARP inhibitor biomarkers market in 2019 owing to increasing patient population suffering from breast cancer, which has increased the demand for early diagnosis of cancer. Key players operating in the global PARP inhibitor biomarkers market are Myriad Genetics, Inc., F. Hoffmann-La Roche AG, Invitae Corporation, NeoGenomics Laboratories, Inc., and BPS Bioscience, Inc. Buy-Now this Research Report @ https://www.coherentmarketinsights.com/insight/buy-now/3762 © Coherent market Insights. All Rights Reserved

5. ABOUT COHERENT MARKET INSIGHTS ABOUT US Coherent Market Insights is a global market intelligence and consulting organization focused on assisting its plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, with an office at the global financial capital in the U.S. Our client base includes players from across all business verticals in over 150 countries worldwide. We are uniquely positioned to help businesses around the globe deliver practical and lasting results through various recommendations about operational improvements, technologies, emerging market trends and new working methods. We offer both customized and syndicated market research reports that help our clients create visionary growth plans to provide traction to their business. We meticulously study emerging trends across various industries at both the global and regional levels to identify new opportunities for our clientele. SERVICES CUSTOMIZED RESEARCH INDUSTRY ANALYSIS SYNDICATED RESEARCH COUNTRY SPECIFIC STUDIES MARKET INTELLIGENCE SERVICES CONSULT STUDIES © Coherent market Insights. All Rights Reserved

6. ABOUT CMI SECTOR COVERAGE BIOTECHNOLOGY CLINICAL DIAGNOSTIC HEALTHCARE IT MEDICAL DEVICES MEDICAL IMAGING PHARMACEUTICAL OUR CLIENTS  Global Leading Equipment and System Manufacturers  Marketing Consultancies and the Advertising Industry  Component Providers and System Integrators  Private and Government organization  Distributors, Retailors and Value Added Resellers  Outsourcing Companies  Healthcare IT Solutions Developers  Universities and Business Schools. © Coherent market Insights. All Rights Reserved

7. KEY STATS RESEARCH SOLUTIONS 100+ GLOBAL REPORTS FEASIBILITY STUDIES Insights Published Per Year CUSTOMIZED SOLUTIONS 150+ COUNTRY ANALYSIS Consulting Projects Till Date CONSULT PROJECTS SURVEY RESEARCH 125+ EXCEL FORECAST DATABASE Clients Worldwide Per Year COMPETITIVE ASSESSMENT TECHNOLOGY SNIPPETS 110+ Analysts and Contract Consultants Coherent Market Insights excels at offering unmatched actionable market intelligence across various industry verticals, including chemicals, healthcare, and food & beverages, to name a few. We implement holistic market research methodology in order to result in the best possible market research reports across various industries worldwide. Based on our unmatched expertise across various industries—no matter how large or small, how complex or unique—we help our clients achieve better outcomes with uniquely designed and highly customized solutions. Our coverage includes insights that help our clients ensure sustained growth in developed markets and also key inputs to help them tap into emerging markets and exploit the plethora of opportunities posed therein. © Coherent market Insights. All Rights Reserved

8. THANK YOU To know more about us, visit our website: www.coherentmarketinsights.com For sales queries or new topics email us on: sales@coherentmarketinsights.com For other queries contact: Mr. Shah (Manager - Business Development) Coherent Market Insights sales@coherentmarketinsights.com +1-206-701-6702 © Coherent market Insights. All Rights Reserved